Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anticancer vaccine

Journal of Immunotherapy

Volumn 20, Issue 1, 1997, Pages 48-59

  Abrams, Scott I ^a   Hodge, James W ^a   McLaughlin, Joanne P ^a   Steinberg, Seth M ^a   Kantor, Judith A ^a   Schlom, Jeffrey ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adoptive immunotherapy; Carcinoembryonic antigen; CD4+ and CD8+ T lymphocytes; Recombinant vaccinia virus

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD8 ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; COLON CARCINOMA; FEMALE; GENETIC RECOMBINATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINE PRODUCTION;

ADENOCARCINOMA; ANIMALS; ANTIBODY SPECIFICITY; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECOMBINATION, GENETIC; SPLEEN; VACCINES, SYNTHETIC;

EID: 0031436616     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199701000-00005     Document Type: Article

References (34)

1. Bystryn J-C. Tumor vaccines. Cancer Metastasis Rev 1990; 9:81-91.
2. + T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. J Immunol 1991;146:3235-41.
3. Kaufman H, Schlom J, Kantor J. A recombinant vaccinia virus expressing human carcinoembryonic antigen. Int J Cancer 1991;48:900-7.
4. McCabe BJ, Irvine KR, Nishimura MI, et al. Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses. Cancer Res 1995;55:1741-7.
5. Wang M, Bronte V, Chen PW, et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol 1995;154:4685-92.
6. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991;49:281-355.
7. Boon T. Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy. Int J Cancer 1993;54:177-180.
8. Roth C, Rochlitz C, Kourilsky P. Immune response against tumors. Adv Immunol 1994;57:281-351.
9. Shu S, Rosenberg SA. Adoptive immunotherapy of newly induced murine sarcomas. Cancer Res 1985;45:1657-62.
10. Shu S, Chou T, Rosenberg SA. In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice. Cancer Res 1987;47:1354-60.
11. Ward BA, Shu S, Chou T, Perry-Lalley D, Chang AE. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma. J Immunol 1988;141:1047-53.
12. Sikorska H, Shuster J, Gold P. Clinical application of carcinoembryonic antigen. Cancer Detect Prev 1988;12:321-55.
13. Thompson JA, Grunert F, Zimmerman W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 1991;5:344-66.
14. Kantor J, Irvine K, Abrams S, Kaufman H, DiPietro J, Schlom J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst 1992;84:1084-91.
15. Kundig TM, Bachmann MF, Lefrancois L, Puddington L, Hengartner H, Zinkernagel RM. Nonimmunogenic tumor cells may efficiently restimulate tumor antigen-specific cytotoxic T cells. J Immunol 1993;150:4450-6.
16. + cytolytic T cells. Nature 1990;344:742-6.
17. Raulet DH. MHC class I-deficient mice. Adv Immunol 1994; 55:381-421.
18. + T-cells. Science 1991;248:1227-30.
19. 2-microglobulin, MHC class I-deficient mice. Proc Natl Acad Sci USA 1993;90:2837-41.
20. + cytotoxic T lymphocyte that mediate specific tumor rejection. J Immunol 1993;151:6283-90.
21. + T cells. J Immunol 1992;149:1319-25.
22. Estin CD, Stevenson US, Plowman GD, et al. Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy. Proc Natl Acad Sci USA 1988;85:1052-6.
23. Bevan MJ. Antigen presentation to cytotoxic T lymphocytes in vivo. J Exp Med 1995;182:639-41.
24. McLaughlin JP, Schlom J, Kantor JA, Greiner JW. Improved immunotherapy of a recombinant CEA vaccinia vaccine when given in combination with interleukin-2. Cancer Res 1996;56:2361-7.
25. Street NE, Mosmann TR. Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J 1991;5:171-7.
26. Hendrzak JA, Brunda MJ. Biology of disease, interleukin-12: biologic activity, therapeutic utility, role in disease. Lab Invest 1995;72:619-37.
27. Kantor J, Irvine K, Abrams S, et al. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res 1992;52:6917-25.
28. Conry RM, Saleh MN, Schlom J, LoBuglio AF. Breaking tolerance to carcinoembryonic antigen with a recombinant vaccinia virus in man. Proc Am Assoc Cancer Res 1995;36:492.
29. Hamilton JM, Chen AP, Nguyen B, et al. Phase I study of recombinant vaccinia virus (rV) that expresses human carcinoembryonic antigen (CEA) in adult patients with adenocarcinomas. ASCO Proc 1994:961.
30. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995;87:982-90.
31. Hodge JW, McLaughlin JP, Abrams SI, Shupert WL, Schlom J, Kantor JA. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor activity. Cancer Res 1995;55:3598-603.
32. Foon KA, Chakraborty M, John WJ, et al. Immune response to the carcinoembryonic antigen in patients treated with anti-idiotype antibody vaccine. J Clin Invest 1995;96:334-42.
33. Fagerberg J, Samanci A, Yi Q, et al. Recombinant carcinoembryonic antigen and granulocyte-macrophage colony-stimulating factor for active immunization of colorectal carcinoma patients. J Immunother 1995;18:132.
34. Philip R, Brunette E, Philip M, Gadol N, Lyerly HK, Lebkowski JS, Alters S. Generation of tumor-specific CTL using genetically modified antigen presenting cells: application in cancer immunotherapy. J Immunother 1995;18:127.